Abstract: Obj ective To observe the efficacy of bortezomib combined with dexamethasone and thalidomide (VTD)in treatment of multiple myeloma (MM).Methods 73 MM patients un-derwent VTD treatment were analyzed.A contemporary cohort of 40 MM patients with VADT chemotherapy was designed as the control group.The prognosis of disease and adverse effects were analyzed.All patients were followed up for 6 months to 2 years.Results The total effective rate of the VTD group was 67 .1%,which was significantly higher than 42 .5%of the VADT group (P<0 .05 ).The rate of response did not differ between VTD and VADT treatments among relapsed/refractory MM patients (P>0 .05 ),but was higher with VTD treatment than that with VADT treatment for newly diagnosed MM patients (P<0 .05 ).The adverse effects of VTD were gastroin-testinal infection,peripheral neuropathy and thrombocytopenia.Conclusion VTD treatment is as-sociated with higher rate of remission in treatment of MM,and therefore it can be used as a first-line option for newly diagnosed and relapsed/refractory patients.